Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Sage Therapeutics to $17 from $21 and keeps a Hold rating on the shares. The firm said they reported Q1 results and are mor eincrementally positive on the stock wshile noting Zurzuvae, which is off to a promising start, could be an underappreciated opportunity over the longer term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics reports Q1 EPS ($1.80), consensus ($1.65)
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
- Sage Therapeutics price target lowered to $19 from $34 at Scotiabank
- Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer